Published in Psychopharmacology (Berl) on December 09, 2003
Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study | NCT00129441
Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature (2011) 8.25
Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol (2006) 4.60
Impairments in frontal cortical gamma synchrony and cognitive control in schizophrenia. Proc Natl Acad Sci U S A (2006) 3.33
Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr Bull (2007) 2.94
GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull (2008) 2.81
Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry (2008) 2.33
N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull (2010) 1.98
The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav Brain Res (2008) 1.84
GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl) (2005) 1.82
In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proc Natl Acad Sci U S A (2005) 1.72
Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry (2008) 1.64
A schizophrenia-related sensorimotor deficit links alpha 3-containing GABAA receptors to a dopamine hyperfunction. Proc Natl Acad Sci U S A (2005) 1.60
Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia. Neuropharmacology (2011) 1.57
Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull (2008) 1.52
Genomic and network patterns of schizophrenia genetic variation in human evolutionary accelerated regions. Mol Biol Evol (2015) 1.48
Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev (2008) 1.46
Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull (2009) 1.45
Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull (2007) 1.45
Steady state responses: electrophysiological assessment of sensory function in schizophrenia. Schizophr Bull (2009) 1.33
Neurotech for neuroscience: unifying concepts, organizing principles, and emerging tools. J Neurosci (2007) 1.28
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology (2009) 1.28
DNA methyltransferase 1 regulates reelin mRNA expression in mouse primary cortical cultures. Proc Natl Acad Sci U S A (2005) 1.26
Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res (2009) 1.20
The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav (2010) 1.16
Linking microcircuit dysfunction to cognitive impairment: effects of disinhibition associated with schizophrenia in a cortical working memory model. Cereb Cortex (2012) 1.09
GABA(A) receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders. Neuropharmacology (2009) 1.09
Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses (2010) 1.06
Extracellular matrix abnormalities in schizophrenia. Neuropharmacology (2011) 1.04
Functional regulation of GABAA receptors in nervous system pathologies. Curr Opin Neurobiol (2011) 1.03
Repeated phencyclidine administration alters glutamate release and decreases GABA markers in the prefrontal cortex of rats. Neuropharmacology (2011) 1.00
Prefrontal cognitive deficits in mice with altered cerebral cortical GABAergic interneurons. Behav Brain Res (2013) 1.00
Altered cortical GABA neurotransmission in schizophrenia: insights into novel therapeutic strategies. Curr Pharm Biotechnol (2012) 0.95
Preferential accumulation of GABAA receptor gamma 2L, not gamma 2S, cytoplasmic loops at rat spinal cord inhibitory synapses. J Physiol (2004) 0.95
GABA and glutamate in schizophrenia: a 7 T ¹H-MRS study. Neuroimage Clin (2014) 0.95
The schizophrenic faces of PICK1. Trends Pharmacol Sci (2006) 0.94
The functional anatomy of schizophrenia: A dynamic causal modeling study of predictive coding. Schizophr Res (2014) 0.92
Update on the neurobiology of schizophrenia: a role for extracellular microdomains. Minerva Psichiatr (2012) 0.91
Postmortem brain: an underutilized substrate for studying severe mental illness. Neuropsychopharmacology (2013) 0.91
Subplate neurons: crucial regulators of cortical development and plasticity. Front Neuroanat (2009) 0.91
Broader visual orientation tuning in patients with schizophrenia. Front Hum Neurosci (2011) 0.90
Cognitive dysfunction associated with anti-glutamic acid decarboxylase autoimmunity: a case-control study. BMC Neurol (2013) 0.89
Contribution of NMDA receptor hypofunction in prefrontal and cortical excitatory neurons to schizophrenia-like phenotypes. PLoS One (2013) 0.89
Cognition-emotion dysinteraction in schizophrenia. Front Psychol (2012) 0.88
Pathways Associating Childhood Trauma to the Neurobiology of Schizophrenia. Front Psychol Behav Sci (2014) 0.88
A predicted binding site for cholesterol on the GABAA receptor. Biophys J (2014) 0.86
Which perspectives can endophenotypes and biological markers offer in the early recognition of schizophrenia? J Neural Transm (Vienna) (2007) 0.84
Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What's the Evidence? Front Psychiatry (2013) 0.82
Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia? Neurotherapeutics (2009) 0.82
The biochemical womb of schizophrenia: A review. Indian J Clin Biochem (2008) 0.82
Bridging Levels of Understanding in Schizophrenia Through Computational Modeling. Clin Psychol Sci (2015) 0.81
The neurobiology of methamphetamine induced psychosis. Front Hum Neurosci (2014) 0.81
Prefrontal cortical GABA transmission modulates discrimination and latent inhibition of conditioned fear: relevance for schizophrenia. Neuropsychopharmacology (2014) 0.81
Pathophysiological power of improper tonic GABA(A) conductances in mature and immature models. Front Neural Circuits (2013) 0.81
Chronic Stress Increases Prefrontal Inhibition: A Mechanism for Stress-Induced Prefrontal Dysfunction. Biol Psychiatry (2016) 0.81
Cognitive ability is associated with altered medial frontal cortical circuits in the LgDel mouse model of 22q11.2DS. Cereb Cortex (2013) 0.80
Prefrontal cortical GABAergic signaling and impaired behavioral flexibility in aged F344 rats. Neuroscience (2016) 0.80
Dopaminergic circuitry and risk/reward decision making: implications for schizophrenia. Schizophr Bull (2014) 0.79
Genetic deletion of fibroblast growth factor 14 recapitulates phenotypic alterations underlying cognitive impairment associated with schizophrenia. Transl Psychiatry (2016) 0.78
New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function. Curr Neuropharmacol (2015) 0.78
Maintenance time of sedative effects after an intravenous infusion of diazepam: a guide for endoscopy using diazepam. World J Gastroenterol (2008) 0.78
Juvenile exposure to ketamine causes delayed emergence of EEG abnormalities during adulthood in mice. Drug Alcohol Depend (2013) 0.77
Vulnerability of synapses in the frontal cortex of mice developmentally exposed to an insecticide: Potential contribution to neuropsychiatric disease. Neurotransmitter (Houst) (2015) 0.77
Pentameric Ligand-gated Ion Channels : Insights from Computation. Mol Simul (2014) 0.76
Emotional and cognitive dysregulation in schizophrenia and depression: understanding common and distinct behavioral and neural mechanisms. Dialogues Clin Neurosci (2015) 0.76
Primary Cilia as a Possible Link between Left-Right Asymmetry and Neurodevelopmental Diseases. Genes (Basel) (2017) 0.75
A case of GABAR antibodies in schizophrenia. BMC Psychiatry (2017) 0.75
Developing therapeutics for schizophrenia and other psychotic disorders. NeuroRx (2005) 0.75
Towards a neurodevelopmental model of clinical case formulation. Psychiatr Clin North Am (2009) 0.75
Investigating Cortical Inhibition in First-Degree Relatives and Probands in Schizophrenia. Sci Rep (2017) 0.75
The NMDA receptor GluN2C subunit controls cortical excitatory-inhibitory balance, neuronal oscillations and cognitive function. Sci Rep (2016) 0.75
Serotonin (5-HT)1A receptor agonism and 5-HT7 receptor antagonism ameliorate the subchronic phencyclidine-induced deficit in executive functioning in mice. Psychopharmacology (Berl) (2015) 0.75
Conflict monitoring and cognitive control. Psychol Rev (2001) 21.52
What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry (1996) 11.03
Excitatory actions of gaba during development: the nature of the nurture. Nat Rev Neurosci (2002) 8.74
Brain-state- and cell-type-specific firing of hippocampal interneurons in vivo. Nature (2003) 7.49
Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry (1995) 7.19
Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A (2001) 6.68
Synchronization of neuronal activity in hippocampus by individual GABAergic interneurons. Nature (1995) 6.33
Interneuron migration from basal forebrain to neocortex: dependence on Dlx genes. Science (1997) 6.08
Turning on and off recurrent balanced cortical activity. Nature (2003) 5.61
Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci (2000) 5.53
Enforcement of temporal fidelity in pyramidal cells by somatic feed-forward inhibition. Science (2001) 5.48
Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry (2000) 5.12
Molecular and neuronal substrate for the selective attenuation of anxiety. Science (2000) 5.07
Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci (2003) 4.86
GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. J Comp Neurol (1995) 4.50
Origin of GABAergic neurons in the human neocortex. Nature (2002) 4.40
International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev (1998) 4.37
Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature (1999) 4.36
Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry (1986) 4.34
Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron (2000) 4.29
Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry (2000) 3.44
Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex (2000) 3.37
Induced gamma-band activity during the delay of a visual short-term memory task in humans. J Neurosci (1998) 3.35
Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. Cereb Cortex (1999) 3.31
Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry (2001) 3.19
Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol (2000) 3.17
Abnormal neural synchrony in schizophrenia. J Neurosci (2003) 3.05
Schizophrenics show spatial working memory deficits. Arch Gen Psychiatry (1992) 3.02
Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. Proc Natl Acad Sci U S A (2002) 2.90
Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J Neurosci (2002) 2.87
The contribution of the anterior cingulate cortex to executive processes in cognition. Rev Neurosci (1999) 2.57
Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry (1991) 2.55
Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull (1984) 2.48
Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry (1997) 2.48
Correlation of physiological subgroupings of nonpyramidal cells with parvalbumin- and calbindinD28k-immunoreactive neurons in layer V of rat frontal cortex. J Neurophysiol (1993) 2.39
Functional hypofrontality and working memory dysfunction in schizophrenia. Am J Psychiatry (1998) 2.25
Local circuit neurons immunoreactive for calretinin, calbindin D-28k or parvalbumin in monkey prefrontal cortex: distribution and morphology. J Comp Neurol (1994) 2.25
Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI. Biol Psychiatry (1999) 2.17
Destruction and creation of spatial tuning by disinhibition: GABA(A) blockade of prefrontal cortical neurons engaged by working memory. J Neurosci (2000) 2.13
Excitatory actions of GABA in the cortex. Neuron (2003) 2.12
Anterior cingulate and prefrontal cortex: who's in control? Nat Neurosci (2000) 2.10
Intact sorting, targeting, and clustering of gamma-aminobutyric acid A receptor subtypes in hippocampal neurons in vitro. J Comp Neurol (2002) 2.08
Differential synaptic localization of two major gamma-aminobutyric acid type A receptor alpha subunits on hippocampal pyramidal cells. Proc Natl Acad Sci U S A (1996) 2.04
A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci U S A (1998) 2.00
Types of neurons, synaptic connections and chemical characteristics of cells immunoreactive for calbindin-D28K, parvalbumin and calretinin in the neocortex. J Chem Neuroanat (1997) 1.96
Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry (1991) 1.94
Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol Psychiatry (2002) 1.83
Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex (2002) 1.77
Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr Res (2002) 1.76
Isodirectional tuning of adjacent interneurons and pyramidal cells during working memory: evidence for microcolumnar organization in PFC. J Neurophysiol (1999) 1.75
Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry (1988) 1.75
Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry (1992) 1.70
Synapse-specific localization of NMDA and GABA(A) receptor subunits revealed by antigen-retrieval immunohistochemistry. J Comp Neurol (1998) 1.65
Local-circuit neurones in the medial prefrontal cortex (areas 25, 32 and 24b) in the rat: morphology and quantitative distribution. J Comp Neurol (1997) 1.64
Functional synergism between putative gamma-aminobutyrate-containing neurons and pyramidal neurons in prefrontal cortex. Proc Natl Acad Sci U S A (1994) 1.61
Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry (1998) 1.60
Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am J Psychiatry (1999) 1.60
GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am J Psychiatry (2001) 1.55
Synchronous development of pyramidal neuron dendritic spines and parvalbumin-immunoreactive chandelier neuron axon terminals in layer III of monkey prefrontal cortex. Neuroscience (1995) 1.55
Functional magnetic resonance imaging brain mapping in psychiatry: methodological issues illustrated in a study of working memory in schizophrenia. Neuropsychopharmacology (1998) 1.54
The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Res (1989) 1.47
Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. Physiol Behav (2002) 1.40
Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. Am J Psychiatry (1997) 1.36
Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience (1996) 1.34
Visualization of chandelier cell axons by parvalbumin immunoreactivity in monkey cerebral cortex. Proc Natl Acad Sci U S A (1989) 1.33
Postnatal development of pre- and postsynaptic GABA markers at chandelier cell connections with pyramidal neurons in monkey prefrontal cortex. J Comp Neurol (2003) 1.29
Heterogeneity of chandelier neurons in monkey neocortex: corticotropin-releasing factor- and parvalbumin-immunoreactive populations. J Comp Neurol (1990) 1.26
Local circuit neurons in the medial prefrontal cortex (areas 24a,b,c, 25 and 32) in the monkey: II. Quantitative areal and laminar distributions. J Comp Neurol (1996) 1.25
Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol Psychiatry (1999) 1.21
Postnatal development of parvalbumin- and GABA transporter-immunoreactive axon terminals in monkey prefrontal cortex. J Comp Neurol (2002) 1.15
Cognitive function in schizophrenia. Int Clin Psychopharmacol (1997) 1.12
Diazepam treatment of early signs of exacerbation in schizophrenia. Am J Psychiatry (1999) 1.09
Prefrontal microcircuits: membrane properties and excitatory input of local, medium, and wide arbor interneurons. J Neurosci (2001) 1.08
Cortical interneuron fate determination: diverse sources for distinct subtypes? Cereb Cortex (2003) 1.07
Parvalbumin-immunoreactive axon terminals in macaque monkey and human prefrontal cortex: laminar, regional, and target specificity of type I and type II synapses. J Comp Neurol (1999) 1.06
Spatial working memory deficits and their relationship to negative symptoms in unmedicated schizophrenia patients. Biol Psychiatry (1996) 1.05
The GABAergic system in schizophrenia. Int J Neuropsychopharmacol (2002) 1.04
A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophr Res (1995) 1.03
Hypofrontality in schizophrenia: RIP. Lancet (1995) 1.02
A highly sensitive immunofluorescence procedure for analyzing the subcellular distribution of GABAA receptor subunits in the human brain. J Histochem Cytochem (1998) 0.99
The frontal lobes, basal ganglia, and temporal lobes as sites for schizophrenia. Schizophr Bull (1990) 0.98
Attentional asymmetry in schizophrenia: controlled and automatic processes. Biol Psychiatry (1992) 0.96
Synaptic targets of the intrinsic axon collaterals of supragranular pyramidal neurons in monkey prefrontal cortex. J Comp Neurol (2001) 0.96
Pyramidal neuron local axon terminals in monkey prefrontal cortex: differential targeting of subclasses of GABA neurons. Cereb Cortex (2003) 0.90
Chandelier cell axons are immunoreactive for GAT-1 in the human neocortex. Neuroreport (1998) 0.83
Neuropsychological bases of schizophrenia. Annu Rev Psychol (1969) 0.82
Cerebral blood flow activation and functional lesions in schizophrenia. Schizophr Res (1996) 0.76
Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci (2005) 11.68
Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci (2003) 4.86
Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci (2011) 3.17
Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features. Am J Psychiatry (2011) 1.91
Alterations of cortical GABA neurons and network oscillations in schizophrenia. Curr Psychiatry Rep (2010) 1.87
Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry (2008) 1.64
Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder. Cereb Cortex (2008) 1.61
A neonatal ventral hippocampal lesion causes functional deficits in adult prefrontal cortical interneurons. J Neurosci (2008) 1.51
Postnatal development of prefrontal inhibitory circuits and the pathophysiology of cognitive dysfunction in schizophrenia. Ann N Y Acad Sci (2004) 1.50
Deficits in transcriptional regulators of cortical parvalbumin neurons in schizophrenia. Am J Psychiatry (2012) 1.40
Lamina-specific alterations in cortical GABA(A) receptor subunit expression in schizophrenia. Cereb Cortex (2010) 1.30
Deciphering the disease process of schizophrenia: the contribution of cortical GABA neurons. Int Rev Neurobiol (2007) 1.20
Altered markers of tonic inhibition in the dorsolateral prefrontal cortex of subjects with schizophrenia. Am J Psychiatry (2009) 1.18
Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia. Neurotox Res (2008) 1.03
Lower gene expression for KCNS3 potassium channel subunit in parvalbumin-containing neurons in the prefrontal cortex in schizophrenia. Am J Psychiatry (2014) 0.97
Selective expression of KCNS3 potassium channel α-subunit in parvalbumin-containing GABA neurons in the human prefrontal cortex. PLoS One (2012) 0.96
Role of glutamic acid decarboxylase 67 in regulating cortical parvalbumin and GABA membrane transporter 1 expression: implications for schizophrenia. Neurobiol Dis (2012) 0.92
Analysis of pyramidal neuron morphology in an inducible knockout of brain-derived neurotrophic factor. Biol Psychiatry (2005) 0.91
Frontal areas contribute to reduced global coordination of resting-state gamma activities in drug-naïve patients with schizophrenia. Schizophr Res (2011) 0.90
Cortical glutamic acid decarboxylase 67 deficiency results in lower cannabinoid 1 receptor messenger RNA expression: implications for schizophrenia. Biol Psychiatry (2011) 0.86
Cortical inhibitory neuron disturbances in schizophrenia: role of the ontogenetic transcription factor Lhx6. Schizophr Bull (2014) 0.81
GABA neurons in the human prefrontal cortex. Am J Psychiatry (2004) 0.81
Inhibition and timing in cortical neural circuits. Am J Psychiatry (2007) 0.78
Neurovascular coupling in the human somatosensory cortex: a single trial study. Neuroreport (2010) 0.78
Selective zif268 mRNA induction in the perirhinal cortex of macaque monkeys during formation of visual pair-association memory. J Neurochem (2002) 0.78
Monitoring gene expression in a single Xenopus oocyte using multiple cytoplasmic collections and quantitative RT-PCR. FEBS J (2013) 0.77
Oxytocin attenuates feelings of hostility depending on emotional context and individuals' characteristics. Sci Rep (2012) 0.77